Literature DB >> 16179584

Mineralocorticoid receptor blocker increases angiotensin-converting enzyme 2 activity in congestive heart failure patients.

Shlomo Keidar1, Aviva Gamliel-Lazarovich, Marielle Kaplan, Elsa Pavlotzky, Shadi Hamoud, Tony Hayek, Rachel Karry, Zaid Abassi.   

Abstract

Aldosterone plays an important role in the pathophysiology of congestive heart failure (CHF), and spironolactone improves cardiovascular function and survival rates in patients with CHF. We hypothesized that the mineralocorticoid receptor blockade (MRB) exerted its beneficial effects by reducing oxidative stress and changing the balance between the counter-acting enzymes angiotensin-converting enzyme (ACE) and ACE2. Monocyte-derived macrophages were obtained from 10 patients with CHF before and after 1 month of treatment with spironolactone (25 mg/d). Spironolactone therapy significantly (P<0.005) reduced oxidative stress, as expressed by reduced lipid peroxide content, superoxide ion release, and low-density lipoprotein oxidation by 28%, 53%, and 70%, respectively. Although spironolactone significantly (P<0.01) reduced macrophage ACE activity by 47% and mRNA expression by 53%, ACE2 activity and mRNA expression increased by 300% and 654%, respectively. In mice treated for 2 weeks with eplerenone (200 mg.kg(-1).d(-1)), cardiac ACE2 activity significantly (P<0.05) increased by 2-fold and was paralleled by increased ACE2 activity in macrophages. The mechanism of aldosterone antagonist action was studied in mouse peritoneal macrophages (MPMs) in vitro. Although ACE activity and mRNA were significantly increased by 250 nmol/L aldosterone, ACE2 was significantly reduced. Cotreatment with eplerenone (2 micromol/L) attenuated these effects. In MPM obtained from p47 knockout mice, where NADPH oxidase is inactive, as well as in control MPMs treated with NADPH oxidase inhibitor, aldosterone did not increase ACE or decrease ACE2. MRB reduced oxidative stress, decreased ACE activity, and increased ACE2 activity, suggesting a protective role for MRB by possibly increasing generation of angiotensin (1-7) and decreasing formation of angiotensin II. These effects are mediated, at least in part, by NADPH oxidase.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16179584     DOI: 10.1161/01.RES.0000187500.24964.7A

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  68 in total

Review 1.  Interference with the renin-angiotensin system in heart failure.

Authors:  R Schulz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-02       Impact factor: 3.000

Review 2.  New physiological concepts of the renin-angiotensin system from the investigation of precursors and products of angiotensin I metabolism.

Authors:  Carlos M Ferrario
Journal:  Hypertension       Date:  2009-12-21       Impact factor: 10.190

Review 3.  ACE2 (Angiotensin-Converting Enzyme 2), COVID-19, and ACE Inhibitor and Ang II (Angiotensin II) Receptor Blocker Use During the Pandemic: The Pediatric Perspective.

Authors:  Andrew M South; Tammy M Brady; Joseph T Flynn
Journal:  Hypertension       Date:  2020-05-05       Impact factor: 10.190

Review 4.  Recombinant human angiotensin-converting enzyme 2 as a new renin-angiotensin system peptidase for heart failure therapy.

Authors:  Gavin Y Oudit; Josef M Penninger
Journal:  Curr Heart Fail Rep       Date:  2011-09

5.  Increasing serum soluble angiotensin-converting enzyme 2 activity after intensive medical therapy is associated with better prognosis in acute decompensated heart failure.

Authors:  Zhili Shao; Kevin Shrestha; Allen G Borowski; David J Kennedy; Slava Epelman; James D Thomas; W H Wilson Tang
Journal:  J Card Fail       Date:  2013-09       Impact factor: 5.712

6.  Mineralocorticoid Receptor Deficiency in Macrophages Inhibits Atherosclerosis by Affecting Foam Cell Formation and Efferocytosis.

Authors:  Zhu-Xia Shen; Xiao-Qing Chen; Xue-Nan Sun; Jian-Yong Sun; Wu-Chang Zhang; Xiao-Jun Zheng; Yu-Yao Zhang; Huan-Jing Shi; Jia-Wei Zhang; Chao Li; Jun Wang; Xu Liu; Sheng-Zhong Duan
Journal:  J Biol Chem       Date:  2016-11-23       Impact factor: 5.157

Review 7.  Intracrine angiotensin II functions originate from noncanonical pathways in the human heart.

Authors:  Carlos M Ferrario; Sarfaraz Ahmad; Jasmina Varagic; Che Ping Cheng; Leanne Groban; Hao Wang; James F Collawn; Louis J Dell Italia
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-05-27       Impact factor: 4.733

Review 8.  Targeting the ACE2-Ang-(1-7) pathway in cardiac fibroblasts to treat cardiac remodeling and heart failure.

Authors:  Michikado Iwata; Randy T Cowling; Seon Ju Yeo; Barry Greenberg
Journal:  J Mol Cell Cardiol       Date:  2010-12-13       Impact factor: 5.000

9.  Tissue-specific regulation of ACE/ACE2 and AT1/AT2 receptor gene expression by oestrogen in apolipoprotein E/oestrogen receptor-alpha knock-out mice.

Authors:  K Bridget Brosnihan; Jeffrey B Hodgin; Oliver Smithies; Nobuyo Maeda; Patricia Gallagher
Journal:  Exp Physiol       Date:  2008-01-11       Impact factor: 2.969

10.  COVID-19, ACE2, and the cardiovascular consequences.

Authors:  Andrew M South; Debra I Diz; Mark C Chappell
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-03-31       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.